It was discovered that pancreatic cancer patients had higher levels of DRD2 expression and that by blocking the extracellular regulated kinase signaling pathway, DRD2 inhibitors could decrease the growth of tumors [63,64]. The gene discussed is DRD2; the disease is familial pancreatic carcinoma.